THE three big Hs – hypertension, hyperlipidemia and high blood sugar – might be able to be controlled by sea buckthorn oil.
A clinical research project in Penang will look into this, following an agreement signed between Usains Infotech Sdn Bhd and Orient Biotech Sdn Bhd. Usains Infotech is a subsidiary of Usains Holdings Berhad, the corporate arm of Universiti Sains Malaysia (USM).
The two-year study aims to look into the effect of Orient Biotech’s supplement product, Sea Buckthorn oil 500mg softgel, and its effectiveness in lowering fasting blood glucose, blood pressure and improving lipid profile.
The oil is derived from the fruits of sea buckthorn, a sub-alpine shrub growing at the foot of mountains in Europe, northwestern Mongolia and northwestern China.
In his speech, Orient Biotech managing director Teoh Eng Sia said World Health Organisation (WHO) announced on June 1 last year that non-communicable diseases (NCDs) killed 41 million people every year, which is equivalent to 71% deaths globally.
“Cardiovascular diseases account for most NCD deaths and claims 17.9 million lives annually.
“NCDs are chronic diseases which tend to be of long duration and are the result of a combination of genetic, physiological, environmental and behavioural factors.
“Hyperglycemia, hypertension and hyperlipidemia are the major root causes of cardiovascular diseases like atherosclerosis or ischemic stroke.
“Fortunately, we also know that the risks associated with the 3Hs can be reduced by supplementation enhancement, healthy eating habits and a healthy lifestyle, ” he said at the agreement signing ceremony in USM on Friday.
Also present was Usains Holding Sdn Bhd managing director Farid Wajidi Mat Yusoff.
Teoh added that by conducting human clinical trials, he hopes that the product will show an improvement in the health and quality of life of patients suffering from the 3Hs.
“The project is solely funded by Orient Biotech as part of its continuing efforts to healthcare. We hope to achieve this by providing appropriate and quality nutraceuticals to 3Hs patients.
“We strongly support industry- university collaborations to produce more socially beneficial health products, ” he said.
Meanwhile, USM deputy vice-chancellor (research and innovation) Professor Datuk Dr Abdul Rahman Mohamed congratulated researchers from various schools and faculties in USM in its collaboration with Orient Biotech.
“Clinical research has already been identified as a key growth engine under the objectives of the 11th Malaysia Plan.
“Thus, evidence-based clinical trials play a key role in advancing human health, especially in testing the latest complementary medicine from nutraceutical and pharmaceutical industries.
“Diabetes mellitus, hypertension and hyperlipidemia are the top three most prevalent contributors of NCD in Malaysia and the government allocates a huge portion of financial support to suffering patients, ” he said in his welcoming remark.
USM School of Industrial Technology principal investigator Dr Lee Lai Kuan said the two-year study will focus on patients suffering from the 3Hs.
“We will be having six groups of 20 patients each.
“Through the study, it will be established whether the supplement manages to control blood sugar, cholesterol and blood pressure levels of the patients, ” she said.
Orient Biotech research and development manager Devyn Lee said the product was launched recently and they are funding the clinical research to prove that their product is effective.
“We hope that through this study, the results will enhance the confidence of 3Hs patients in our product.
“Our product is available in all pharmacies across Malaysia, ” he said.
Details are found in www.ebonlife.com
Orient Biotech is a natural health food manufacturer based in Selangor and has served numerous organisations including foreign companies since 1995.
As a veteran in the health food and nutraceuticals industry for the past 20 years, Orient Biotech is set up based on three key strengths: sound industry knowledge, hands- on manufacturing experience and innovation.